Pfad >>
HAL Allergy
Profile
HAL Allergy is one of the leading companies in the field of allergen diagnostic and immunotherapies in Europe. The allergy therapies are used against common allergies such as hay fever, house dust mites allergy and allergic reactions towards wasp or bee stings. The company works intensively in collaboration with its sales organizations, distributors and internationally acclaimed research institutes to bring out the best possible combination of knowledge and experience. The company focuses on the core group of allergy experts from the specialties of ENT, Dermatology and Pulmonology. HAL Allergy has the most modern and state-of-the-art production facility at its main site in the Bio Science Park at Leiden in the Netherlands. Currently their products are marketed in 16 countries. Moreover this leading manufacturer of therapeutic and diagnostic agents for allergies has sales organizations in all the major European markets including Germany, Poland, Austria, Italy and Spain.
Headquarters
Leiden, Netherlands
Value enhancement strategy
- Clinical Research – Europe-wide product approvals for the overall portfolio
- R&D – Development of new immune therapies for respiratory and food allergens
- Sales Force Excellence – Dealing with its core customer group through its own distribution company
- Internationalisation – Focus on new markets - Asia, USA
Sector
Pharmaceutical Industry
Acquisition of share
December 2007
Website
Management Team
HAL Allergy Group
![[Translate to Englisch:] Harry Flore, CEO HAL Allergy Group](fileadmin/_processed_/0/b/csm_hal_allergy_h.flore_cf838c5032.jpg)
Dr. Harry Flore, CEO HAL Allergy
News about Hal Allergy
Hans van Schijndel appointed as Chief Research & Development Officer of HAL Allergy Holding B.V.
With this appointment, the Board of Directors is now complete. Next to Dr. Hans van Schijndel, in charge of the R&D program, the Board consists of...
Dr. Harry Flore honored with Royal Decoration
The CEO of our platform HAL Allergy Group and boardmember of HALIX, was honored by His Majesty the King of the Netherlands for his career and...
HAL Allergy achieves marketing authorisations in line with Therapieallergene-Verordnung
HAL Allergy B.V. today announced the registration of SUBLIVAC® Birch 40.000 AUN/ml and SUBLIVAC® Trees 40.000 AUN/ml in Germany. These are the first...
BioScience as a Service: HALIX is expanding its capacity for sustainable growth
HALIX is gearing up for the future and significantly increases its capacity by building a new, highly efficient facility for biopharmaceutical...
HAL Allergy: myAllergy mit Digital Health Heroes Award 2017 ausgezeichnet
Anlässlich des 12. Deutschen Allergiekongresses in Wiesbaden, vom 05. bis 07. Oktober 2017, wurde die Internetplattform myAllergy (www.allergy.de) mit...
HAL allergy: myAllergy geht online
Neue Informationsplattform rund um Allergien mit Fachwissen und Expertenrat
HAL Allergy: First In-Human study peanut allergy
HAL Allergy has successfully completed the First-In-Human study with their subcutaneous immunotherapeutic drug for peanut allergy.
HAL Allergy: next step in a short-term efficacy trial
HAL Allergy has successfully completed its Phase III short-term efficacy trial with its sublingual allergen immunotherapy (SLIT) liquid product for...